Wenxue Zhao1, Miao Lu2, Xiangming Wang2, Yan Guo3. 1. Department of Gerontology, The Second Affiliated Hospital of Nanjing Medical University, 262 Zhongshan North Road, Gulou District, Nanjing, 210003, Jiangsu, People's Republic of China. 1990919407@qq.com. 2. Department of Gerontology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, Jiangsu, People's Republic of China. 3. Department of Gerontology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Gulou District, Nanjing, 210029, Jiangsu, People's Republic of China. guoyan51@hotmail.com.
Abstract
OBJECTIVES: To compare the diagnostic value of the SARC-F, MRSA-7 and MRSA-5 questionnaires in screening for sarcopenia in inpatients with chronic heart failure (CHF). PATIENTS: A total of 355 CHF patients hospitalized from January 2019 to August 2019 who met the study's selection criteria were included in the analysis. MEASUREMENTS: Handgrip strength and gait speed were measured, and bioelectrical impedance analysis (BIA) was used to estimate appendicular skeletal muscle mass. The sensitivity/specificity of the SARC-F, MRSA-7 and MRSA-5 questionnaires was evaluated. RESULTS: The diagnostic criteria of the Asia Working Group for Sarcopenia (AWGS) were used as the gold standard for diagnosing sarcopenia. The prevalence of sarcopenia was 55.8% according to the AWGS diagnostic criteria, 31.0% according to the SARC-F, 73.0% according to the MRSA-7, and 71.3% according to the MRSA-5. Using the AWGS criteria as the gold standard, the SARC-F had a sensitivity of 52.5% and a specificity of 96.2% in the whole study population, the MRSA-7 had a sensitivity of 92.4% and a specificity of 51.6%, and the MRSA-5 had a sensitivity of 93.9% and a specificity of 57.3%. The areas under the ROC curves for the SARC-F, MRSA-7 and MRSA-5 were 0.78, 0.74 and 0.77, respectively. CONCLUSIONS: The MSRA-7 and MSRA-5 may serve as novel screening tools for sarcopenia in hospitalized patients with CHF. The SARC-F, a classic screening tool, is also suitable for this population. The MSRA-7 and MSRA-5 have better sensitivity, whereas the SARC-F has better specificity.
OBJECTIVES: To compare the diagnostic value of the SARC-F, MRSA-7 and MRSA-5 questionnaires in screening for sarcopenia in inpatients with chronic heart failure (CHF). PATIENTS: A total of 355 CHF patients hospitalized from January 2019 to August 2019 who met the study's selection criteria were included in the analysis. MEASUREMENTS: Handgrip strength and gait speed were measured, and bioelectrical impedance analysis (BIA) was used to estimate appendicular skeletal muscle mass. The sensitivity/specificity of the SARC-F, MRSA-7 and MRSA-5 questionnaires was evaluated. RESULTS: The diagnostic criteria of the Asia Working Group for Sarcopenia (AWGS) were used as the gold standard for diagnosing sarcopenia. The prevalence of sarcopenia was 55.8% according to the AWGS diagnostic criteria, 31.0% according to the SARC-F, 73.0% according to the MRSA-7, and 71.3% according to the MRSA-5. Using the AWGS criteria as the gold standard, the SARC-F had a sensitivity of 52.5% and a specificity of 96.2% in the whole study population, the MRSA-7 had a sensitivity of 92.4% and a specificity of 51.6%, and the MRSA-5 had a sensitivity of 93.9% and a specificity of 57.3%. The areas under the ROC curves for the SARC-F, MRSA-7 and MRSA-5 were 0.78, 0.74 and 0.77, respectively. CONCLUSIONS: The MSRA-7 and MSRA-5 may serve as novel screening tools for sarcopenia in hospitalized patients with CHF. The SARC-F, a classic screening tool, is also suitable for this population. The MSRA-7 and MSRA-5 have better sensitivity, whereas the SARC-F has better specificity.